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Summary 1 
Background: Rucaparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, has shown 2 
anticancer activity in patients with recurrent ovarian carcinoma which harbours a BRCA 3 
mutation or has a high percentage of genome-wide loss of heterozygosity (LOH). 4 
ARIEL3 evaluated rucaparib versus placebo following response to second-line or later 5 
platinum-based chemotherapy in patients with high-grade, recurrent platinum-sensitive 6 
ovarian carcinoma. 7 
Methods: ARIEL3 is an international, randomised, double-blind phase 3 study 8 
performed at 87 hospitals and cancer centres in which randomised patients receive oral 9 
rucaparib 600 mg twice daily or placebo. The primary endpoint (investigator-assessed 10 
progression-free survival) was evaluated using an ordered step-down procedure for 11 
three nested cohorts: (1) BRCA mutant (carcinoma associated with deleterious germline 12 
or somatic BRCA mutation); (2) homologous recombination deficient (HRD) (BRCA 13 
mutant or BRCA wild type/LOH high); and (3) intent-to-treat population. ARIEL3 is 14 
registered with ClinicalTrials.gov, NCT01968213; enrolment is complete. 15 
Findings: Between April 7, 2014 and July 19, 2016, 564 patients (intent-to-treat 16 
population) were randomised, 375 to rucaparib and 189 to placebo. Median 17 
progression-free survival in patients with a BRCA-mutant carcinoma (n=130, rucaparib; 18 
n=66, placebo) was 16.6 months versus 5.4 months (p<0.0001), respectively (hazard 19 
ratio [HR], 0.23; 95% confidence interval [CI], 0.16-0.34); in patients with an HRD 20 
carcinoma (n=236, rucaparib; n=118, placebo) was 13.6 months versus 5.4 months 21 
(p<0.0001), respectively (HR, 0.32; 95% CI, 0.24-0.42); and in the intent-to-treat 22 
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population was 10.8 months and 5.4 months (p<0.0001), respectively (HR, 0.37; 95% 23 
CI, 0.30-0.45). The most common grade 3 or higher treatment-emergent adverse events 24 
in the safety population (n=372, rucaparib; n=189, placebo) were anaemia/decreased 25 
haemoglobin (70 [18.8%], rucaparib; one [0.5%], placebo) and increased alanine 26 
aminotransferase or aspartate aminotransferase (39 [10.5%], rucaparib; none, placebo).  27 
Interpretation: Across all primary analysis groups, rucaparib significantly improved 28 
progression-free survival in patients with platinum-sensitive ovarian cancer who had 29 
achieved a response to platinum-based chemotherapy. 30 
Funding: Clovis Oncology, Inc. 31 
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Research in context 32 
Evidence before this study 33 
Evidence of the clinical effectiveness of poly(ADP-ribose) polymerase (PARP) inhibitors 34 
as maintenance treatment for platinum-sensitive ovarian carcinoma is limited. In a 35 
search of PubMed (conducted July 31, 2017; search term: (“PARP inhibitor” OR 36 
rucaparib OR olaparib OR niraparib OR veliparib OR talazoparib) AND (ovarian AND 37 
(cancer OR carcinoma)) AND "maintenance"), we found that data have been published 38 
in a PubMed-indexed journal for only three clinical trials, Study 19 (NCT00753545), 39 
NOVA (NCT01847274), and SOLO2 (NCT01874353). The first of these, Study 19, a 40 
randomised, placebo-controlled, phase 2 study, enrolled patients with platinum-sensitive 41 
ovarian carcinoma who had received at least two prior platinum-based chemotherapies. 42 
Progression-free survival was significantly improved with olaparib maintenance 43 
treatment in the overall population as well as in patients with a germline or somatic 44 
BRCA mutation. Study 19 data were published prior to the commencement of ARIEL3 45 
and its results supported the investigation of rucaparib as a maintenance treatment for 46 
patients with recurrent platinum-sensitive ovarian carcinoma in ARIEL3. In late 2016, 47 
results from the NOVA trial provided additional support for the role of a PARP inhibitor 48 
as maintenance treatment. In that randomised, placebo-controlled, phase 3 study, 49 
niraparib demonstrated a significant improvement in progression-free survival when 50 
used as a maintenance treatment in patients with ovarian carcinoma with or without a 51 
germline BRCA mutation who had received at least two prior platinum-based 52 
chemotherapies and had residual disease less than 2 cm. Results from one other phase 53 
3 study with olaparib maintenance treatment, SOLO2, were published in July 2017. That 54 
randomised, placebo-controlled study enrolled patients with platinum-sensitive ovarian 55 
carcinoma who had received at least two prior platinum-based chemotherapies and 56 
carried a germline mutation in BRCA. Similar to the results seen in Study 19, 57 
progression-free survival was significantly improved with olaparib maintenance 58 
treatment in patients enrolled in the study. 59 
Added value of this study 60 
ARIEL3 enrolled patients with or without a germline or somatic BRCA mutation, and 61 
size of residual disease was not restricted. Our results show that rucaparib maintenance 62 
treatment significantly improved progression-free survival for patients across all primary 63 
analysis groups for patients with recurrent, platinum-sensitive ovarian carcinoma who 64 
achieved a response to platinum-based therapy, including in the intent-to-treat 65 
population. We demonstrate that rucaparib maintenance treatment can provide clinical 66 
benefit not only to patients with ovarian carcinoma associated with a BRCA mutation, 67 
but also to those with BRCA wild-type ovarian carcinoma. A novel aspect of the ARIEL3 68 
trial was the prospective validation of the tumour-based, next-generation sequencing 69 
(NGS) homologous recombination deficiency (HRD) assay that was used in the phase 2 70 
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ARIEL2 study, which combines mutation analysis of BRCA1 and BRCA2 genes with 71 
measurement of the percentage of genome-wide loss of heterozygosity (LOH) in the 72 
carcinoma as a biomarker for sensitivity to rucaparib treatment. ARIEL2 enrolled 73 
patients with measurable, recurrent ovarian carcinoma, and provided initial evidence 74 
that patients with carcinomas with high LOH benefited from rucaparib treatment. The 75 
current study (ARIEL3) validated the utility of the HRD assay overall and LOH 76 
assessment in particular in the maintenance treatment setting, where rucaparib-treated 77 
patients with carcinomas that were BRCA wild type/LOH high also had improvements in 78 
progression-free survival, with a lower hazard ratio than in patients with carcinomas that 79 
were BRCA wild type/LOH low.  80 
Implications of all the available evidence 81 
Combined with the evidence from prior studies, our study supports the use of PARP 82 
inhibitors such as rucaparib as maintenance treatment for patients with platinum-83 
sensitive ovarian cancer who achieved a response to platinum-based chemotherapy, 84 
including patients who have bulky residual disease. ARIEL3 is the first phase 3 study to 85 
prospectively assess progression-free survival in patients with recurrent ovarian 86 
carcinoma associated with HRD as a primary endpoint, and our results demonstrate 87 
that HRD as a predictive biomarker can be an informative tool for clinicians when 88 
making treatment decisions for this patient population. In addition to PARP inhibitors, 89 
the targeted agents bevacizumab and cediranib have proven useful in extending 90 
progression-free survival for patients in this setting. Our findings strengthen the 91 
rationale for continued investigation of targeted therapies for maintenance treatment, 92 
such as PARP inhibitors, alone and in combination with other agents, in an effort to 93 
provide the best care for patients with advanced ovarian cancer.   94 
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INTRODUCTION 95 
Ovarian cancer is the eighth leading cause of death from cancer in women worldwide.1 96 
Most patients with advanced stage ovarian carcinoma initially receive platinum-based 97 
chemotherapy and achieve a clinical response; however, the majority of these patients 98 
will ultimately relapse.2 The treatment for initial recurrent disease depends on many 99 
factors, including duration of initial treatment response, antecedent and persistent 100 
adverse events, performance status, histology, location and burden of disease, and, 101 
increasingly, tumour genomics such as BRCA mutation status.3 For patients with 102 
platinum-sensitive recurrent ovarian carcinoma, maintenance treatment with targeted 103 
agents has resulted in greater prolongation of progression-free survival.4-9 However, 104 
clinical benefit is typically transient, hence there is an ongoing pursuit for new therapies, 105 
tools to identify patients who may benefit most from these therapies, and the optimal 106 
therapeutic strategy for patients.  107 
The poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib is approved in the United 108 
States for the treatment of patients with deleterious BRCA mutation (germline or 109 
somatic) associated advanced ovarian carcinoma who have been treated with two or 110 
more chemotherapy regimens. Approval of rucaparib was based on the objective 111 
response rate (53.8%, n=106) observed in a pooled population of patients with BRCA-112 
mutant high-grade ovarian carcinoma from the Study 10 (CO-338-10; NCT01482715) 113 
and ARIEL2 (CO-338-017; NCT01891344) clinical trials.10,11   114 
In Part 1 of the ARIEL2 trial, rucaparib treatment was found to be efficacious not only in 115 
patients with relapsed, platinum-sensitive, high-grade ovarian carcinoma with a BRCA 116 
ARIEL3 Primary Manuscript  21-Sep-17 
10 
 
mutation, but also in patients with BRCA wild-type carcinomas with high genomic loss of 117 
heterozygosity (LOH),11 a potential marker for homologous recombination deficiency 118 
(HRD) and thus PARP inhibitor activity.12-15 In the current phase 3, randomised, 119 
placebo-controlled study (ARIEL3), our objective was to evaluate the efficacy and safety 120 
of rucaparib versus placebo following response to second-line or later platinum-based 121 
chemotherapy in patients with high-grade, platinum-sensitive ovarian carcinoma 122 
(including fallopian tube and primary peritoneal carcinomas) and to prospectively test 123 
the genomic LOH cutoff that was optimized based on results of ARIEL2 Part 1 as a 124 
predictive biomarker for sensitivity to rucaparib treatment. 125 
 126 
METHODS 127 
Study design and patients 128 
ARIEL3 (NCT1968213) was a phase 3, international, randomised, placebo-controlled 129 
study conducted at 87 hospitals and cancer centres in Australia, Belgium, Canada, 130 
France, Germany, Israel, Italy, New Zealand, Spain, United Kingdom, and the United 131 
States. The trial was approved by national or local institutional review boards and was 132 
carried out in accordance with the Declaration of Helsinki and Good Clinical Practice 133 
Guidelines of the International Conference on Harmonisation. Patients provided written 134 
informed consent before participation. Per the protocol, an independent data monitoring 135 
committee monitored enrolment and reviewed the safety and efficacy of the trial at 136 
regular intervals, including maturity of progression-free survival events. 137 
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Eligible patients were aged 18 years or older and had platinum-sensitive (ie, 138 
documented radiologic disease progression more than 6 months following the last dose 139 
of the penultimate platinum administered), high-grade serous or endometrioid ovarian, 140 
primary peritoneal, or fallopian tube carcinoma following at least two prior platinum-141 
based chemotherapy regimens. Prior treatment with bevacizumab was permitted, with 142 
the exception of bevacizumab maintenance treatment following the most recent 143 
platinum-based regimen. On November 4, 2014 an amendment was added to the 144 
protocol restricting the most recent platinum-based regimen to a chemotherapy doublet 145 
administered for a minimum of four cycles (ie, bevacizumab or other biologics were not 146 
allowed as part of the most recent therapy). Patients must have achieved either a 147 
complete response by Response Evaluation Criteria In Solid Tumors version 1.1 148 
(RECIST)16 or a partial response, defined as either a RECIST partial response or a 149 
serologic response per Gynecologic Cancer InterGroup (GCIG) cancer antigen 125 150 
(CA-125)17 response criteria, to their last platinum-based regimen. For patients who 151 
achieved a partial response, no restriction was placed on residual carcinoma size at 152 
study entry; those that had persistent lesions greater than 2 cm were defined as having 153 
bulky residual disease. Responses must have been maintained through the completion 154 
of chemotherapy and during the interval period between completion of chemotherapy 155 
and entry into ARIEL3. Additionally, CA-125 was required to be less than the upper limit 156 
of normal. Patients had Eastern Cooperative Oncology Group Performance Status of 0 157 
to 1 and adequate organ function. Patients were ineligible if they had an active second 158 
malignancy or symptomatic/untreated central nervous system metastases, had received 159 
anticancer therapy less than 14 days before starting the study, or had received prior 160 
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treatment with a PARP inhibitor. A complete list of inclusion and exclusion criteria is 161 
provided in the appendix (p 6); and the full study protocol is available in the appendix.  162 
Central testing of archival tumour tissue samples was performed to detect mutations in 163 
homologous recombination pathway genes (appendix p 8) and assess genomic LOH 164 
using Foundation Medicine’s T5 next-generation sequencing assay (Cambridge, MA). 165 
Based on retrospective analysis of data from ARIEL2 Part 1, a cutoff of 16% or greater 166 
for high genomic LOH was prespecified for ARIEL3.11 Germline mutations were 167 
identified by BRCAnalysis CDx test (Myriad Genetics). Further details of the tumour 168 
tissue testing are provided in the appendix (p 2).  169 
Randomisation and masking 170 
Within 8 weeks of their last dose of platinum, eligible patients were randomised 2:1 to 171 
receive oral rucaparib (600 mg twice daily) or matched placebo. Randomisation was 172 
computer-generated by Almac Clinical Technologies (Craigavon, United Kingdom) using 173 
a block size of six. Randomisation stratification factors included: HRD status (based on 174 
gene mutation only); progression-free interval following penultimate platinum-based 175 
regimen; and best response to most recent platinum-based regimen (additional details 176 
in the appendix p 3). Patients were assigned to the rucaparib arm or placebo arm in a 177 
blinded manner using Almac Clinical Technologies’ interactive web and voice response 178 
system (IXRS®); patients, investigators, site staff, and the study sponsor were blinded to 179 
assignments. To ensure blinding was maintained, rucaparib and placebo tablets were 180 
manufactured to have identical appearances.   181 
ARIEL3 Primary Manuscript  21-Sep-17 
13 
 
Procedures 182 
Patients received study drug in continuous 28-day cycles until disease progression, 183 
death, or other reason for discontinuation. Dose reductions (in decrements of 120 mg) 184 
were permitted if a patient had a grade 3 or greater adverse event (additional details in 185 
the appendix p 3). Treatment was discontinued for a toxicity-related dose interruption 186 
lasting more than 14 consecutive days (unless otherwise agreed upon between the 187 
investigator, the study’s joint lead clinical investigators, and the study sponsor). 188 
Disease assessments were performed at screening, every 12 weeks, at discontinuation 189 
of treatment, and as clinically indicated. Disease progression was determined by 190 
RECIST. Patients with a complete response at study entry were only considered to 191 
have disease progression if an unequivocal new lesion was identified; increased CA-192 
125 levels alone were not considered to indicate disease progression unless confirmed 193 
by RECIST. All computed tomography scans and other imaging were provided to a 194 
blinded, independent central radiology review (BICR). 195 
The National Comprehensive Cancer Network-Functional Assessment of Cancer 196 
Therapy (NCCN-FACT) Ovarian Symptom Index 18 (FOSI-18)18 questionnaire was 197 
used to assess patient-reported outcomes at screening and throughout treatment.  198 
Safety was assessed by monitoring for adverse events, laboratory testing, assessing 199 
vital signs and conducting physical examinations. Adverse events were classified in 200 
accordance with the Medical Dictionary for Drug Regulatory Activities classification 201 
system version 18.119 and graded for severity in accordance with the National Cancer 202 
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Institute Common Terminology Criteria for Adverse Events version 4.03.20 Serious 203 
adverse events were classified as defined in the protocol (see appendix).  204 
Outcomes 205 
The primary endpoint was investigator-assessed progression-free survival, defined as 206 
time from randomisation to investigator-assessed disease progression per RECIST or 207 
death. Secondary endpoints included progression-free survival by BICR, patient-208 
reported outcomes as evaluated by time to worsening in the FOSI-18 disease-related 209 
symptoms–physical (DRS-P) subscale (defined as ≥4 point decrease) and total score 210 
(defined as ≥8 point decrease), overall survival, safety, and population pharmacokinetic 211 
modelling. Additional details are available in the appendix (p 3). The secondary 212 
endpoint of population pharmacokinetic modelling will be reported separately. 213 
Statistical Analysis 214 
ARIEL3 was designed to enrol 540 patients, including between 180 and 200 patients 215 
with a BRCA mutation in their carcinoma (with no more than 150 patients with a known 216 
deleterious germline BRCA mutation) and no more than 360 patients without a BRCA 217 
mutation in their carcinoma. These subgroup sizes were designed to result in 90% 218 
power to determine statistical significance between rucaparib and placebo at a one-219 
sided alpha level of 0.025 given the following assumptions for median investigator-220 
assessed progression-free survival for the efficacy analysis cohorts: BRCA mutant 221 
(carcinoma associated with a deleterious germline or somatic BRCA mutation), 12.0 222 
months in the rucaparib arm versus 6.0 months in the placebo arm (hazard ratio [HR], 223 
0.5); HRD (includes patients with a BRCA-mutated carcinoma and patients with BRCA 224 
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wild-type/LOH high carcinomas), 10.0 versus 6.0 months (HR, 0.6); and intent-to-treat 225 
population (all randomised patients), 8.5 versus 6.0 months (HR, 0.7). 226 
Classification of HRD status in the carcinoma (based on BRCA mutation and/or LOH) 227 
for the efficacy analysis was determined before database lock and the final efficacy 228 
analysis. Per protocol, the primary analysis was to be performed after the independent 229 
data monitoring committee determined that investigator-assessed disease progression 230 
or death had occurred in at least 70% of expected patients in the BRCA-mutant cohort.  231 
All efficacy analyses were performed for the intent-to-treat population. The efficacy 232 
analyses are presented separately for the nested cohorts: BRCA mutant, HRD, and 233 
intent-to-treat population. The primary endpoint was tested using an ordered step-down 234 
multiple comparisons procedure21,22 for the three nested cohorts: BRCA mutant, HRD, 235 
and the intent-to-treat population. Investigator-assessed progression-free survival in 236 
patients with a BRCA-mutant carcinoma was tested first at a one-sided 0.025 237 
significance level. Analysis of investigator-assessed progression-free survival in patients 238 
with an HRD carcinoma followed by analysis in the intent-to-treat population was 239 
contingent upon a statistically significant result in the analysis of patients with a BRCA-240 
mutant carcinoma. Analysis of the key secondary endpoints of patient-reported 241 
outcomes and overall survival were to follow in a similar ordered step-down procedure. 242 
Once statistical significance was not achieved for one test, the statistical significance 243 
was not declared for all subsequent analyses in the ordered step-down procedure. 244 
Progression-free survival by BICR was evaluated as a key stand-alone secondary 245 
endpoint, separate from the step-down procedure described above. Time to 246 
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progression-free survival (by investigator and by BICR) and time to worsening in the 247 
FOSI-18 DSR-P subscale were analysed using stratified Kaplan-Meier methodology 248 
where distributions between rucaparib and placebo arms were compared using a 249 
stratified log-rank test. A stratified Cox proportional hazards model was used to estimate 250 
the HR between the arms. Exploratory analyses of progression-free survival were 251 
performed in subgroups based on patient characteristics (eg, randomisation 252 
stratification factors, disease burden at baseline). The proportion of patients achieving 253 
an objective response was an exploratory endpoint of ARIEL3, and was determined by 254 
the proportion of patients with measurable disease at study entry who achieved a best 255 
response of complete or partial response per RECIST as assessed by investigator.  256 
Safety, including adverse events and clinical laboratory investigations, was evaluated in 257 
all patients who received at least one dose of protocol-specified treatment.  258 
Statistical analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC). 259 
Additional details are available in the appendix (p 4). 260 
Role of the funding source 261 
The study was designed by the sponsor, Clovis Oncology, Inc., and the coordinating 262 
investigators (RLC and JAL). Data presented herein were collected by the investigators, 263 
analysed by Clovis Oncology, and interpreted by all authors. All authors had access to 264 
the data. Writing and editorial assistance were supported by the sponsor. 265 
RESULTS 266 
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Between April 7, 2014 and July 19, 2016, 564 patients (intent-to-treat population) were 267 
randomised, 375 to rucaparib and 189 to placebo (figure 1; appendix p 11). At the visit 268 
cutoff date (April 15, 2017), 90 (24.0%) and 9 (4.8%) patients in the rucaparib and 269 
placebo arms, respectively, were still receiving treatment. Baseline demographic and 270 
clinical characteristics were generally well balanced between the treatment arms (table 271 
1).  272 
Following the ordered step-down multiple comparisons procedure, the analysis of 273 
investigator-assessed progression-free survival was evaluated first in patients with a 274 
BRCA-mutant carcinoma (130, rucaparib; 66, placebo; appendix p 11). Median time to 275 
progression or death was 16.6 months versus 5.4 months (stratified log-rank p<0.0001) 276 
in the rucaparib and placebo arms, respectively (HR, 0.23; 95% confidence interval [CI], 277 
0.16-0.34; p<0.0001) (figure 2). In patients with an HRD carcinoma (236, rucaparib; 278 
118, placebo), median progression-free survival was 13.6 months and 5.4 months 279 
(stratified log-rank p<0.0001), respectively, (HR, 0.32; 95% CI, 0.24-0.42; p<0.0001). 280 
Median progression-free survival in the intent-to-treat population was 10.8 months and 281 
5.4 months (stratified log-rank p<0.0001), respectively (HR, 0.37; 95% CI, 0.30-0.45; 282 
p<0.0001).    283 
In a prespecified analysis of the key stand-alone, secondary endpoint of progression-284 
free survival assessed by BICR, results were similar to those of investigator-assessed 285 
progression-free survival for the patients with a BRCA-mutant carcinoma (median 26.8 286 
months vs. 5.4 months; HR, 0.20; 95% CI, 0.13-0.32; p<0.0001), the patients with an 287 
HRD carcinoma (median 22.9 months vs. 5.5 months; HR, 0.34; 95% CI, 0.24-0.47; 288 
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p<0.0001), and the intent-to-treat population (median 13.7 months vs. 5.4 months; HR, 289 
0.35; 95% CI, 0.28-0.45; p<0.0001) (figure 2).  290 
Analysis of the secondary endpoint of time to worsening in the FOSI-18 DRS-P 291 
subscale score was assessed in the step-down procedure for the three nested 292 
subgroups. In patients with a BRCA-mutant carcinoma, there was no significant 293 
between-arm difference in the time to worsening in the FOSI-18 DRS-P subscale 294 
(stratified log-rank p=0.29) (HR, 1.24; 95% CI, 0.82−1.86; p=0.30). As statistical 295 
significance was not reached in patients with a BRCA-mutant carcinoma, in accordance 296 
with the prespecified step-down procedure, statistical significance could not be 297 
determined for the remaining secondary analyses. Additional details on health-related 298 
quality of life will be reported separately. 299 
At the visit cutoff date (April 15, 2017), overall survival data were not mature. Overall, 300 
during the study follow-up 123 (21.8%) patients had died. A follow-up analysis will be 301 
performed when approximately 70% of the patients have died.   302 
Preplanned subgroup analyses of investigator-assessed progression-free survival 303 
demonstrated that the progression-free survival benefit for rucaparib versus placebo 304 
was observed across all clinical subgroups, irrespective of presence or absence of 305 
measurable disease or bulky disease (defined as any lesion >2 cm) at baseline, 306 
response to last platinum-based regimen (complete or partial response), LOH (high, 307 
low, or indeterminate), or BRCA mutation (germline or somatic; BRCA1 or BRCA2) 308 
(figure 3; appendix p 12). In patients with carcinomas that were BRCA wild type, a 309 
progression-free survival benefit was observed with rucaparib in patients with LOH-high 310 
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carcinomas (median 9.7 months vs. 5.4 months; HR, 0.44; 95% CI, 0.29-0.66; 311 
p<0.0001) and patients with LOH-low carcinomas (median 6.7 months vs. 5.4 months; 312 
HR, 0.58; 95% CI, 0.40-0.85; p=0.0049) (figure 4); similar results were also observed in 313 
the progression-free survival assessed by BICR (appendix p 13).   314 
The majority of patients (374 [66.3%]) in ARIEL3 had achieved a partial response to the 315 
platinum-based therapy received prior to randomisation. A prespecified exploratory 316 
analysis of objective response was conducted in 207 of these 374 patients (55.3%) who 317 
had investigator-assessed, RECIST-measurable disease at baseline. In evaluable 318 
patients with a BRCA-mutant carcinoma, 15 of 40 (37.5%) in the rucaparib arm and two 319 
of 23 (8.7%) in the placebo arm achieved a confirmed RECIST response (appendix p 320 
8). In patients with an HRD carcinoma with measurable disease at baseline, the 321 
objective response was also higher in the rucaparib arm (23 of 85 [27.1%] patients) than 322 
the placebo arm (3 of 41 [7.3%] patients). A similar result was observed in the intent-to-323 
treat population among patients with measurable disease at baseline (26 of 141 [18.4%] 324 
patients in the rucaparib arm; 5 of 66 [7.6%] patients in the placebo arm). Complete 325 
responses were observed in the rucaparib arm in seven (17.5%), 10 (11.8%), and 10 326 
(7.1%) patients with measurable disease at baseline in the nested BRCA-mutant and 327 
HRD cohorts, and the overall intent-to-treat population, respectively. Only one (1.5%) 328 
complete response was observed in the placebo arm, and this occurred in the intent-to-329 
treat population.  330 
In the safety population (372, rucaparib; 189, placebo), the median (interquartile range 331 
[IQR]) treatment duration was 8.3 (3.4-16.1) months in the rucaparib arm and 5.5 (2.8-332 
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8.3) months in the placebo arm. A treatment-emergent adverse event of any grade 333 
occurred in 372 (100.0%) patients in the rucaparib arm and 182 (96.3%) patients in the 334 
placebo arm (table 2). The most common treatment-emergent adverse events (reported 335 
in at least 35% of patients in either arm) included nausea (280 [75.3%] patients in the 336 
rucaparib arm and 69 [36.5%] patients in the placebo arm), asthenia or fatigue (258 337 
[69.4%] patients and 83 [43.9%] patients), dysgeusia (146 [39.2%] patients and 13 338 
[6.9%] patients), anaemia/decreased haemoglobin (139 [37.4%] patients and 11 [5.8%] 339 
patients), constipation (136 [36.6%] patients and 45 [23.8%] patients), and vomiting 340 
(136 [36.6%] patients and 28 [14.8%] patients). Treatment-emergent adverse events of 341 
grade 3 or greater were reported in 209 (56.2%) patients in the rucaparib arm and 28 342 
(14.8%) patients in the placebo arm, the most common of which were 343 
anaemia/decreased haemoglobin (70 [18.8%] patients in the rucaparib arm and one 344 
[0.5%] patient in the placebo arm) and increase in alanine aminotransferase or 345 
aspartate aminotransferase (39 [10.5%] patients and no patients). For patients in the 346 
rucaparib arm, a decline in haemoglobin level from baseline generally occurred in the 347 
first few cycles (appendix p 14). Elevations in alanine aminotransferase or aspartate 348 
aminotransferase were generally transient, self-limiting, and not associated with other 349 
signs of liver toxicity (appendix p 15). The frequency of treatment-emergent adverse 350 
events was comparable across the three nested cohorts. 351 
One or more serious adverse events were reported in 78 (21.0%) patients in the 352 
rucaparib arm and 20 (10.6%) patients in the placebo arm. The most common serious 353 
adverse events (reported in at least 1.5% of patients in either arm) included anaemia 354 
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(16 [4.3%] patients in the rucaparib arm and one [0.5%] patient in the placebo arm), 355 
pyrexia (six [1.6%] patients and no patients), vomiting (six [1.6%] patients and two 356 
[1.1%] patients), and small intestinal obstruction (three [0.8%] patients and three [1.6%] 357 
patients).  358 
Myelodysplastic syndrome and acute myeloid leukaemia were reported in three (0.8%) 359 
patients in the rucaparib arm (two had a germline BRCA-mutant carcinoma, and one 360 
had a BRCA wild-type/LOH low carcinoma). One patient died due to myelodysplastic 361 
syndrome and one due to acute myeloid leukaemia. There were no reports of 362 
myelodysplastic syndrome or acute myeloid leukaemia in the placebo arm.  363 
Dose reduction due to a treatment-emergent adverse event occurred in 203 (54.6%) 364 
and 8 (4.2%) patients in the rucaparib and placebo arms, respectively (appendix p 9). 365 
Treatment interruption due to a treatment-emergent adverse event occurred in 237 366 
(63.7%) and 19 (10.1%) patients in the rucaparib and placebo arms, respectively 367 
(appendix p 9). In the rucaparib and placebo arms, 117 (31.5%) and 6 (3.2%) patients, 368 
respectively, had both a dose reduction due to a treatment-emergent adverse event and 369 
a treatment interruption due to a treatment-emergent adverse event during the study. Of 370 
patients who received rucaparib, 50 (13.4%) discontinued due to a treatment-emergent 371 
adverse event (excluding disease progression) compared with three (1.6%) of patients 372 
in the placebo arm (appendix p 10). As of the visit cutoff date, there were six deaths due 373 
to adverse events in the rucaparib arm: two patients due to progressive disease, one 374 
due to acute myeloid leukaemia, one due to cardiac arrest, one due to haematophagic 375 
histiocytosis, and one due to myelodysplastic syndrome. In the placebo arm, two 376 
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patients died due to adverse events: one due to progressive disease, and one due to 377 
pulmonary embolism. 378 
 379 
DISCUSSION 380 
In ARIEL3, rucaparib maintenance treatment versus placebo significantly improved 381 
progression-free survival in all primary analysis groups of patients with recurrent ovarian 382 
carcinoma following a complete or partial response to platinum-based therapy. The 63% 383 
reduction in risk of disease progression or death observed for patients receiving 384 
rucaparib in the intent-to-treat population demonstrates that patients with platinum-385 
sensitive ovarian carcinoma can derive robust clinical benefit from rucaparib 386 
maintenance treatment. A similar reduction (65%) in risk of disease progression or 387 
death was seen in the secondary endpoint of assessment by blinded, independent 388 
central radiology review, supporting the validity of the benefit observed with rucaparib 389 
maintenance treatment.  Furthermore, the lower risk of disease progression or death 390 
associated with rucaparib was observed across all prespecified subgroups that were 391 
analysed. Analysis of non-nested, non-overlapping patient subpopulations (ie, BRCA 392 
wild-type/LOH high and BRCA wild-type/LOH low patients) indicate that the statistically 393 
significant improvement in progression-free survival observed in the intent-to-treat 394 
population was not driven only by the results in the nested HRD or BRCA-mutant 395 
cohorts.  396 
Patient-reported outcomes were evaluated as a secondary endpoint of ARIEL3 as part 397 
of the step-down procedure, with no significant difference in time to worsening in the 398 
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FOSI-18 DRS-P subscale observed between the rucaparib and placebo arms. Further 399 
analyses of the health-related quality of life data gathered in ARIEL3 are planned and 400 
will be reported separately.  401 
Overall survival data were not mature at the time of the visit cut off, with less than 20% 402 
of the events needed for final analysis. Follow-up of patients is continuing in a blinded 403 
manner and overall survival will be assessed after about 70% maturity is reached. 404 
As reported in prior studies of rucaparib and other PARP inhibitors,5,6,9-11,23 405 
gastrointestinal side effects, asthenia or fatigue, and myelosuppression were common 406 
treatment-emergent adverse events in the rucaparib arm. Management of adverse 407 
events included supportive care and dose modifications (including treatment interruption 408 
and dose reductions). Common laboratory abnormalities observed in the rucaparib arm 409 
included elevations in alanine aminotransferase, aspartate aminotransferase, and blood 410 
creatinine. Alanine aminotransferase and aspartate aminotransferase were not 411 
associated with abnormal increases in bilirubin or other criteria for drug-induced 412 
hepatotoxicity, and generally resolved over time. Similarly, elevations in creatinine, 413 
which have also been observed with olaparib,24 were self-limiting and stabilized over 414 
time. Creatinine is secreted into urine via renal transporters (eg, MATE1, MATE2-K, 415 
OCT-1 and OCT-2), which have been shown to be inhibited in vitro by multiple PARP 416 
inhibitors, including rucaparib, olaparib, and veliparib.25-27 Patterns of elevation and 417 
stabilization of these laboratory abnormalities similar to those reported here were 418 
observed in the treatment setting with rucaparib.28,29   419 
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The results of ARIEL3 are consistent with those of other placebo-controlled studies of 420 
PARP inhibitors in the maintenance treatment setting, including NOVA (NCT01847274) 421 
with niraparib and Study 19 (NCT00753545) and SOLO2 (NCT01874353) with 422 
olaparib.5,6,9 However, direct comparisons with these other trials cannot be made due to 423 
differences in study design (eg, residual disease was restricted to less than 2 cm in 424 
NOVA), patient groups analysed (eg, SOLO2 only enrolled patients with a germline 425 
BRCA mutation), definition of HRD (eg, in NOVA, HRD included patients with somatic 426 
mutations in BRCA, as well as those with nonBRCA-related HRD), and the method of 427 
primary endpoint assessment (eg, investigator vs BICR).5,6,9,30  428 
Similar to other studies of PARP inhibitors in the maintenance treatment setting,5,6,9 429 
patients were required to have CA-125 below the upper limit of normal prior to entry into 430 
ARIEL3. While not a requirement of response per GCIG CA-125 criteria or a RECIST 431 
partial response, this eligibility requirement supported that patients had controlled 432 
disease at study entry. It is possible that even greater benefit for rucaparib maintenance 433 
treatment may have been observed in a setting where CA-125 was not required to be 434 
below the upper limit of normal at baseline. 435 
Although ARIEL3 extends the findings of previous studies of PARP inhibitors in this 436 
setting, there are some important differences between ARIEL3 and other studies in the 437 
maintenance treatment setting. Notably, patients in ARIEL3 with carcinomas associated 438 
with a germline or somatic BRCA mutation were both included in the three nested 439 
cohorts (BRCA mutant, HRD, and intent-to-treat population), a feature that is unique to 440 
ARIEL3 among clinical trials in this setting. In addition, ARIEL3 did not restrict 441 
enrolment based on carcinoma size for patients with residual disease (partial response 442 
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to prior platinum). A number of patients with measurable residual disease at study entry 443 
showed further reduction in carcinoma burden with rucaparib maintenance treatment, 444 
including conversions to complete responses.  445 
In addition, ARIEL3 is the first phase 3 study to prospectively assess progression-free 446 
survival in patients with recurrent ovarian carcinoma associated with HRD as a primary 447 
endpoint. Preplanned analysis of progression-free survival in patients with a BRCA wild-448 
type/LOH high carcinoma, wherein patients treated with rucaparib had a 56% decrease 449 
in risk of disease progression or death compared with placebo, shows that the 450 
improvement observed in the HRD cohort was not driven solely by patients with a 451 
BRCA-mutant carcinoma. The lower risk of disease progression or death seen in 452 
patients with a BRCA wild-type/LOH high carcinoma (HR, 0.44) compared with patients 453 
with a BRCA wild-type/LOH low carcinoma (HR, 0.58) demonstrates the utility of HRD, 454 
in particular high genomic LOH as defined by Foundation Medicine’s T5 assay, as a 455 
predictive biomarker for sensitivity to rucaparib treatment. Based on our findings, HRD 456 
assessment may be an informative tool for informing clinicians when making treatment 457 
decisions for patients with BRCA wild-type associated platinum-sensitive ovarian 458 
carcinoma. However, activity of rucaparib was also clearly observed in the cohort of 459 
patients with carcinomas that were not associated with HRD, with over 30% of patients 460 
in the rucaparib arm achieving benefit of more than a year’s duration compared with 461 
less than 10% in the placebo arm. Therefore, the biomarker does not appear to be 462 
sufficiently precise to predict benefit or lack of benefit on an individual basis. 463 
In summary, rucaparib improved progression-free survival in women with platinum-464 
sensitive ovarian carcinoma following a complete or partial response to second-line or 465 
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later platinum-based chemotherapy. Treatment-emergent adverse events in the 466 
rucaparib arm were generally managed with dose interruptions or modifications and 467 
were not associated with increased mortality or morbidity compared with the placebo 468 
arm.  469 
 470 
 471 
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TABLES 
Table 1. Baseline patient and disease characteristics. 
Characteristic 
Rucaparib 
(n=375) 
Placebo 
(n=189) 
Age (years) 61.0 (53.0-67.0) 62.0 (53.0-68.0) 
Race   
White 302 (80.5%) 149 (78.8%) 
Non-white 26 (6.9%) 13 (6.9%) 
Unknown 47 (12.5%) 27 (14.3%) 
ECOG Performance Status   
0 280 (74.7%) 136 (72.0%) 
1 94 (25.3%) 53 (28.0%) 
Diagnosis   
Epithelial ovarian cancer 312 (83.2%) 159 (84.1%) 
Fallopian tube cancer 32 (8.5%) 10 (5.3%) 
Primary peritoneal cancer 31 (8.3%) 19 (10.1%) 
High grade serous adenocarcinoma* 0 (0%) 1 (0.5%) 
Histology   
Serous 357 (95.2%) 179 (94.7%) 
Endometrioid 16 (4.3%) 7 (3.7%) 
Mixed 1 (0.3%) 3 (1.6%) 
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Transitional 1 (0.3%) 0 (0%) 
BRCA mutation in the carcinoma   
BRCA mutant 130 (34.7%) 66 (34.9%) 
BRCA1 80 (21.3%) 37 (19.6%) 
BRCA2 50 (13.3%) 29 (15.3%) 
Germline 82 (21.9%) 48 (25.4%) 
Somatic 40 (10.7%) 16 (8.5%) 
Unknown† 8 (2.1%) 2 (1.1%) 
BRCA wild-type 245 (65.3%) 123 (65.1%) 
LOH high 106 (28.3%) 52 (27.5%) 
LOH low 107 (28.5%) 54 (28.6%) 
LOH indeterminate‡ 32 (8.5%) 17 (9.0%) 
Number of prior chemotherapy regimens  2 (2-3) 2 (2-3) 
2 231 (61.6%) 124 (65.6%) 
≥3 144 (38.4%) 65 (34.4%) 
Prior bevacizumab use§ 83 (22.1%) 43 (22.8%) 
Number of platinum-based regimens 2 (2-3) 2 (2-3) 
2 236 (62.9%) 126 (66.7%) 
≥3 139 (37.1%) 63 (33.3%) 
Measurable disease at baseline (per investigator) 141 (37.6%) 66 (34.9%) 
Bulky disease (any lesion >2 cm) at baseline 71 (18.9%) 29 (15.3%) 
Randomisation stratification factors   
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HRD gene mutation status   
BRCA mutant 130 (34.7%) 66 (34.9%) 
Mutation in other, non-BRCA homologous 
recombination gene 
28 (7.5%) 15 (7.9%) 
No mutation detected 217 (57.9%) 108 (57.1%) 
Time to progression with penultimate platinum 
(months) 
13.8  
(10.0-22.3) 
14.6  
(10.7-24.0) 
6 to <12 months 151 (40.3%) 76 (40.2%) 
≥12 months 224 (59.7%) 113 (59.8%) 
Response to last platinum    
CR per RECIST  126 (33.6%) 64 (33.9%) 
PR per RECIST or serologic response per 
GCIG CA-125 criteria 
249 (66.4%)  125 (66.1%) 
Data are median (IQR) or n (%). CA-125=cancer antigen 125; CR=complete response; 
ECOG=Eastern Cooperative Oncology Group; GCIG=Gynecologic Cancer InterGroup; 
HRD=homologous recombination deficiency; LOH=loss of heterozygosity; PR=partial response; 
RECIST=Response Evaluation Criteria In Solid Tumors version 1.1. *Per patient records, origin was 
fallopian tube and/or ovary. †Tumour sample was BRCA positive by Foundation Medicine’s T5 next-
generation sequencing assay but a blood sample was not available for central germline testing. 
‡Tumour sample was not evaluable for percent of genomic LOH due to low tumour content or low 
aneuploidy. §Prior treatment with bevacizumab was permitted as part of penultimate or earlier 
treatment. 
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Table 2. Treatment emergent adverse events of any grade reported in ≥10% of 
patients in either arm. 
 
Rucaparib 
(n=372) 
Placebo 
(n=189) 
 
Any 
Grade 
Grade 
1–2 
Grade 
3 
Grade 
4 
Any 
Grade 
Grade 
1–2 
Grade 
3 
Grade 
4 
At least one AE 372* 
(100.0%) 
163 
(43.8%) 
179 
(48.1%) 
24 
(6.5%) 
182† 
(96.3%) 
154 
(81.5%) 
24 
(12.7%) 
2 
(1.1%) 
Blood and lymphatic system disorders 
Anaemia; decreased 
haemoglobin 
139 
(37.4%) 
69 
(18.5%) 
67 
(18.0%) 
3 
(0.8%) 
11 
(5.8%) 
10 
(5.3%) 0 
1 
(0.5%) 
Neutropenia; neutrophil count 
decreased 
67 
(18.0%) 
42 
(11.3%) 
19 
(5.1%) 
6 
(1.6%) 
9 
(4.8%) 
7 
(3.7%) 
1 
(0.5%) 
1 
(0.5%) 
Thrombocytopenia; platelet 
count decreased 
104 
(28.0%) 
85 
(22.8%) 
13 
(3.5%) 
6 
(1.6%) 
5 
(2.6%) 
5 
(2.6%) 0 0 
Gastrointestinal disorders 
Abdominal distension 41 
(11.0%) 
41 
(11.0%) 
0 0 22 
(11.6%) 
22 
(11.6%) 
0 0 
Abdominal pain 111 
(29.8%) 
102 
(27.4%) 
9 
(2.4%) 0 
49 
(25.9%) 
48 
(25.5%) 
1 
(0.5%) 0 
Abdominal pain (upper) 52 
(14.0%) 
50 
(13.4%) 
2 
(0.5%) 0 
10 
(5.3%) 
10 
(5.3%) 0 0 
Constipation 136 
(36.6%) 
129 
(34.7%) 
7 
(1.9%) 0 
45 
(23.8%) 
43 
(22.8%) 
2 
(1.1%) 0 
Diarrhoea 118 
(31.7%) 
116 
(31.2%) 
2 
(0.5%) 0 
41 
(21.7%) 
39 
(7.9%) 
2 
(1.1%) 0 
Dyspepsia 54 
(14.5%) 
53 
(14.2%) 
1 
(0.3%) 0 
9 
(4.8%) 
9 
(4.8%) 0 0 
Nausea 280 
(75.3%) 
266 
(71.5%) 
14 
(3.8%) 0 
69 
(36.5%) 
68 
(36.0%) 
1 
(0.5%) 0 
Vomiting 136 
(36.6%) 
121 
(32.5%) 
15 
(4.0%) 0 
28 
(14.8%) 
26 
(13.8%) 
2 
(1.1%) 0 
General disorders and administration site conditions 
Asthenia; fatigue 258 
(69.4%) 
233 
(62.6%) 
25 
(6.7%) 0 
83 
(43.9%) 
78 
(41.3%) 
5 
(2.6%) 0 
Oedema peripheral 39 
(10.5%) 
38 
(10.2%) 
1 
(0.3%) 0 
14 
(7.4%) 
14 
(7.4%) 0 0 
Pyrexia 44 
(11.8%) 
44 
(11.8%) 0 0 
8 
(4.2%) 
8 
(4.2%) 0 0 
Infections and infestations 
Upper respiratory tract infection 41 
(11.0%) 
41 
(11.0%) 0 0 
6 
(3.2%) 
4 
(2.1%) 
2 
(1.1%) 0 
Investigations 
Increase in alanine 
aminotransferase or aspartate 
aminotransferase‡ 
126 
(33.9%) 
87 
(23.4%) 
39 
(10.5%) 0 
7 
(3.7%) 
7 
(3.7%) 0 0 
Increase in blood creatinine 57 
(15.3%) 
56 
(15.1%) 
1 
(0.3%) 0 
3 
(1.6%) 
3 
(1.6%) 0 0 
Metabolism and nutrition disorders 
Decreased appetite 87 
(23.4%) 
85 
(22.8%) 
2 
(0.5%) 0 
26 
(13.8%) 
26 
(13.8%) 0 0 
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Hypomagnesaemia 40 
(10.8%) 
39 
(10.5%) 
1 
(0.3%) 0 
11 
(5.8%) 
11 
(5.8%) 0 0 
Musculoskeletal and connective tissue disorders 
Arthralgia 57 
(15.3%) 
55 
(14.8%) 
2 
(0.5%) 0 
24 
(12.7%) 
24 
(12.7%) 0 0 
Back pain 45 
(12.1%) 
45 
(12.1%) 0 0 
28 
(14.8%) 
28 
(14.8%) 0 0 
Nervous system disorders 
Dizziness 54 
(14.5%) 
54 
(14.5%) 0 0 
15 
(7.9%) 
14 
(7.4%) 
1 
(0.5%) 0 
Dysgeusia 146 
(39.2%) 
146 
(39.2%) 0 0 
13 
(6.9%) 
13 
(6.9%) 0 0 
Headache 67 
(18.0%) 
66 
(17.7%) 
1 
(0.3%) 0 
30 
(15.9%) 
29 
(15.3%) 
1 
(0.5%) 0 
Psychiatric disorders 
Insomnia 53 
(14.2%) 
53 
(14.2%) 
0 0 15 
(7.9%) 
15 
(7.9%) 
0 0 
Respiratory, thoracic and mediastinal disorders 
Cough 54 
(14.5%) 
54 
(14.5%) 0 0 
25 
(13.2%) 
25 
(13.2%) 0 0 
Dyspnoea 50 
(13.4%) 
50 
(13.4%) 0 0 
14 
(7.4%) 
14 
(7.4%) 0 0 
Skin and subcutaneous tissue disorders 
Photosensitivity reaction 64 
(17.2%) 
62 
(16.7%) 
2 
(0.5%) 0 
1 
(0.5%) 
1 
(0.5%) 0 0 
Pruritus 47 
(12.6%) 
47 
(12.6%) 0 0 
19 
(10.1%) 
19 
(10.1%) 0 0 
Rash 46 
(12.4%) 
45 
(12.1%) 
1 
(0.3%) 0 
17 
(9.0%) 
17 
(9.0%) 0 0 
Data are n (%) in the safety population, all patients who received at least one dose of protocol-specified treatment. 
*Includes six patients with a grade 5 treatment-emergent adverse event. †Includes two patients with a grade 5 
treatment-emergent adverse event. ‡Elevations were transient, self-limiting, and not associated with other signs of liver 
toxicity. 
 
  
ARIEL3 Primary Manuscript  21-Sep-17 
41 
 
FIGURES 
Figure 1: CONSORT diagram 
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Figure 2: Investigator-assessed and blinded, central independent radiology 
review-assessed progression-free survival  
Kaplan-Meier estimates of progression-free survival as assessed by the investigator (A-
C) and by BICR (D-F) in the rucaparib (blue) and placebo (red) arms for (A, D) patients 
with a BRCA-mutant carcinoma, (B, E) patients with an HRD carcinoma, and (C, F) the 
intent-to-treat population.  
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BICR=blinded, independent central radiology review; CI=confidence interval; 
HRD=homologous recombination deficient; NR=not reached.
ARIEL3 Primary Manuscript  21-Sep-17 
44 
 
Figure 3: Investigator-assessed progression-free survival in subgroups of the 
intent-to-treat population 
 
CA-125=cancer antigen 125; CI=confidence interval; CR=complete response; 
GCIG=Gynecologic Cancer InterGroup; HR=hazard ratio; ITT=intent-to-treat; LOH=loss 
of heterozygosity; PR=partial response; RECIST=Response Evaluation Criteria In Solid 
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Tumors version 1.1. *By local germline test, central germline test, or tumour testing. 
†Tumour sample was not evaluable for percent of genomic LOH due to low tumour 
content or low aneuploidy. ‡Prior treatment with bevacizumab was permitted as part of 
penultimate or earlier treatment. 
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Figure 4. Investigator-assessed progression-free survival in patients with a BRCA 
wild-type carcinoma  
Kaplan-Meier estimates of progression-free survival as assessed by the investigator in 
the rucaparib (blue) and placebo (red) arms for patients with a BRCA wild-type 
carcinoma with (A) LOH high and (B) LOH low. 
CI=confidence interval; HR=hazard ratio; LOH=loss of heterozygosity. 
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Australia – M. Buck, A. Dean, M. L. Friedlander, J. Goh, P. Harnett, G. Kichenadasse, C. L. Scott; Belgium – H. 
Denys, L. Dirix, I. Vergote; Canada – L. Elit, P. Ghatage, A. M. Oza, M. Plante, D. Provencher, J. I. Weberpals, S. 
Welch; France – A. Floquet, L. Gladieff, F. Joly, A. Leary, A. Lortholary, J. Lotz, J. Medioni, O. Tredan, B. You; 
Germany – A. El-Balat, C. Hänle, P. Krabisch, T. Neunhöffer, M. Pölcher, P. Wimberger; Israel – A. Amit, S. 
Kovel, M. Leviov, T. Safra, R. Shapira-Frommer, S. Stemmer; Italy – A. Bologna, N. Colombo, D. Lorusso, S. 
Pignata, R. F. Sabbatini, G. Scambia, S. Tamberi, C. Zamagni; New Zealand – P. C. Fong, A. O'Donnell; Spain – 
M. Amenedo Gancedo, A. Casado Herraez, J. Garcia-Donas, E. M. Guerra, A. Oaknin, I. Palacio, I. Romero, A. 
Sanchez; United Kingdom – S. N. Banerjee, A. Clamp, Y. Drew, H. G. Gabra, D. Jackson, J. A. Ledermann, I. A. 
McNeish, C. Parkinson, M. Powell; United States – C. Aghajanian, D. K. Armstrong, M. J. Birrer, M. K. Buss, S. 
K. Chambers, L-m. Chen, R. L. Coleman, R. W. Holloway, G. E. Konecny, L. Ma, M. A. Morgan, R. T. Morris, D. 
G. Mutch, D. M. O'Malley, B. M. Slomovitz, E. M. Swisher, T. Vanderkwaak, M. Vulfovich 
SUPPLEMENTAL METHODS 
Patient inclusion/exclusion criteria 
A full list of inclusion and exclusion criteria are provided in Table S1. Patients must have achieved either a complete 
response by Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST) or a partial response, defined as 
either a RECIST partial response or a serologic response per Gynecologic Cancer InterGroup (GCIG) cancer antigen 
125 (CA-125) response criteria, to their last platinum-based regimen. All responses required that CA-125 be less 
than the upper limit of normal.  
Next-generation sequencing of tumour biopsies 
Patients were required to provide sufficient archival formalin-fixed paraffin-embedded tumour tissue (1 × 4 µm 
section for haematoxylin and eosin stain and approximately 8 to 12 × 10 µm sections, or equivalent) for analyses of 
mutations in homologous recombination pathway genes (Table S2) and assessment of genomic loss of 
heterozygosity (LOH) using Foundation Medicine’s T5 next-generation sequencing assay performed at the central 
testing facility (Cambridge, MA). A cutoff of 16% or greater was defined as the optimum cutoff following a 
retrospective analysis of data from ARIEL2 Part 11 and was prespecified for high genomic LOH. The most recently 
collected tumour tissue sample was preferred. BRCA1 or BRCA2 (BRCA) mutation results were provided to patients 
and investigators upon availability; results for other mutations were provided upon study treatment discontinuation. 
Investigators were not blinded to BRCA mutation status because patients could enrol with a known germline BRCA 
mutation (limited to 150 patients), and presence of a BRCA mutation detected upon analysis of tumour tissue during 
the study was provided to consenting patients and investigators. Germline mutations were identified by 
BRCAnalysis CDx test (Myriad Genetics). 
Tumours were designated in the following ways: 
• Germline BRCA mutant: deleterious BRCA mutation detected by both next-generation sequencing of 
tumour tissue and central germline blood test 
• Somatic BRCA mutant: deleterious BRCA mutation detected by next-generation sequencing of tumour 
tissue but not by central germline blood test 
• BRCA wild type: deleterious BRCA mutation not detected by next-generation sequencing of tumour tissue 
• LOH high: genomic LOH of 16% or greater as detected by next-generation sequencing of tumour tissue 
• LOH low: genomic LOH of less than 16% as detected by next-generation sequencing of tumour tissue 
• LOH indeterminate: not evaluable for percent of genomic LOH due to low tumour content or low 
aneuploidy in the biopsy 
These designations were used to categorise patients into the following non-nested, non-overlapping subgroups: 
• BRCA mutant (a deleterious germline or somatic BRCA mutation in the carcinoma) 
• BRCA wild type/LOH high 
• BRCA wild type/LOH low 
• BRCA wild type/LOH indeterminate 
ARIEL3 Primary Manuscript  21-Sep-17 
3 
 
Randomisation stratification 
Randomisation stratification factors included: homologous recombination deficiency (HRD) status (based on gene 
mutation only); progression-free interval following penultimate platinum-based regimen (6 to 12 or more than 12 
months); and best response to most recent platinum-based regimen (complete or partial response). Stratification 
based on HRD as assessed by gene mutation status of tumour tissue was as follows: mutation in BRCA1 or BRCA2 
(BRCA mutant), mutation in a non-BRCA gene associated with homologous recombination from a 28-gene panel 
(Table S2), or no mutation in BRCA or a homologous recombination panel gene.  
Treatment and assessments 
Study drug could be taken with or without food. Supportive care (eg, analgesics for pain control or antiemetics) was 
permitted at the investigator’s discretion. Patients who discontinued treatment for a reason other than disease 
progression or death continued to have tumour scans performed at 12-week intervals (up to 1 week prior was 
permitted) until disease progression, as assessed by the investigator. Patient-reported outcomes using the Functional 
Assessment of Cancer Therapy Ovarian Symptom Index 18 (FOSI-18) instrument were assessed at screening, day 1 
of every treatment cycle, and treatment discontinuation. All patients who discontinued from treatment (regardless of 
reason) were followed for 28 days for assessment of adverse events and patient reported outcomes. Patients were 
also followed for survival, subsequent treatments, and monitoring for secondary malignancy every 12 weeks until 
death, loss to follow up, withdrawal of consent, or study closure.  
Dose modification criteria 
Rucaparib was to be reduced if any of the following were observed: grade 3 or 4 haematologic toxicity; grade 3 or 4 
nonhaematologic toxicity (except for alopecia, nausea, vomiting, or diarrhoea adequately controlled with systemic 
antiemetic/antidiarrheal medication administered in standard doses according to the study centre routines). 
Additionally, rucaparib may have been held and/or reduced at the discretion of the investigator for grade 2 toxicity 
not adequately controlled by concomitant medications and/or supportive care. Rucaparib was to be held until the 
toxicity resolved to grade 2 or less. 
Secondary endpoint definitions 
The time to an event of worsening in the FOSI-18 disease-related symptoms–physical (DRS-P) subscale was defined 
as time from randomisation to a 4-point reduction in the DRS-P subscale. The time to an event of worsening in the 
total score of the FOSI-18 was defined as the time from randomisation to an 8-point reduction in the total score. 
Overall survival is defined as the number of days from the date of randomisation to the date of death (due to any 
cause). Progression-free survival by independent radiology review was defined as the time from randomisation to 
disease progression, according to RECIST criteria as assessed by independent radiology review, or death due to any 
cause, whichever occurs first. Safety endpoints included incidence of adverse events, clinical laboratory 
abnormalities, and dose modifications. The population pharmacokinetics endpoint included individual model 
parameter estimates of rucaparib and covariates identification. 
Efficacy analysis of subgroups  
The primary endpoint of investigator-assessed progression-free survival was further explored in prespecified 
categories, including the following: 
• Randomization stratification factors 
o BRCA mutant, mutation in non-BRCA homologous recombination repair (HRR) gene on list used 
for randomisation stratification (Table S2), no mutation in HRR gene on list used for 
randomisation stratification 
o Interval between completion of the penultimate platinum-based regimen and disease progression 
(6 to 12 months or > 12 months) 
o Best response (complete response per RECIST or partial response per RECIST and/or GCIG CA-
125 response) to platinum regimen received immediately prior to initiation of rucaparib 
maintenance therapy 
• HRD definition used for efficacy analysis (BRCA mutant, BRCA wild-type/LOH high, BRCA wild-
type/LOH low, BRCA wild-type/LOH indeterminate) 
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• Age groups (<65, 65-74, ≥75) 
• Race (white, non-white) 
• Subgroups based on disease burden at baseline 
o Measurable disease: all patients who have measurable disease (ie, target lesion of any size) at 
baseline as assessed by the investigator and/or independent radiology reviewer. 
o No disease: all patients who have no target lesions or non-target disease at baseline as assessed by 
the investigator and/or independent radiology reviewer. 
o No bulky disease: all patients with any/all lesions less than 2 cm in the shortest axis (lymph nodes) 
or longest axis (all other lesions) as assessed by the independent reviewer. 
• Subgroups based on gene mutation and type 
o BRCA mutation (BRCA1 or BRCA2) 
o BRCA mutation origin (germline, somatic, unknown) 
o Combining the patients with a tumour with a somatic BRCA mutation and the patients with a 
tumour with LOH high 
o Intent-to-treat population excluding patients with a tumour harbouring a BRCA mutation that is 
germline in origin 
In addition, investigator-assessed PFS was explored in a retrospective analysis in patients with and without prior 
bevacizumab as part of their penultimate or earlier treatment. 
Exploratory endpoint 
The proportion of patients achieving an objective response was an exploratory endpoint of ARIEL3, and was 
determined by the proportion of patients with measurable disease at study entry who achieved a best response of 
complete or partial response per RECIST as assessed by both investigator and independent radiology review.    
Statistical analysis 
The primary endpoint was tested using an ordered step-down multiple comparisons procedure for three nested 
cohorts: BRCA mutant, HRD, and the intent-to-treat population. Investigator-assessed progression-free survival in 
patients with a BRCA-mutant carcinoma was tested first at a one-sided 0.025 significance level. Analysis of 
investigator-assessed progression-free survival in patients with an HRD carcinoma followed by analysis in the 
intent-to-treat population was contingent upon a statistically significant result in analysis of patients with a BRCA-
mutant carcinoma. As with the primary endpoint, analysis of key secondary endpoints followed in an ordered step-
down procedure, starting with patient-reported outcomes using DRS-P subscale of the FOSI-18, then patient-
reported outcomes using total FOSI-18 score, and then overall survival. Once statistical significance was not 
achieved for one test the statistical significance was not declared for all subsequent analyses in the ordered step-
down procedure.  
Time-to-event variables (eg, progression-free survival) were calculated with Kaplan-Meier methodology. For 
progression-free survival, patients without documented progression were censored as of their last tumour 
assessment. Patients without a 4-point reduction in the FOSI-18 DRS-P subscale score were censored on the date of 
their last patient-reported outcome evaluation. Time-to-event distributions between the randomised arms were using 
a stratified log-rank test. Hazard ratios were estimated using the Cox proportional hazards model. Exact 95% 
confidence intervals for the objective response rate were determined using the Clopper-Pearson method. 
The primary and secondary efficacy endpoints were also evaluated in the non-nested, non-overlapping subgroups of 
BRCA mutant, BRCA wild type/LOH high, BRCA wild type/LOH low, and BRCA wild type/LOH indeterminate to 
ensure that the results in the HRD cohort were not solely driven by the results in the BRCA-mutant cohort and the 
results in the intent-to-treat population were not solely driven by the results of the HRD cohort. To claim a 
significant result in the HRD cohort, the size of the estimated effect in patients with carcinomas with BRCA wild 
type/LOH high was required to be clinically relevant and at least as large as what would be needed to achieve 
‘‘statistical significance’’ in an analysis conducted in the entire HRD population. Similarly, for the results in the 
intent-to-treat population to be considered significant and not solely driven by the results of the BRCA-mutant or 
HRD cohorts, the size of the estimated effect in patients with carcinomas with BRCA wild type/LOH low and BRCA 
wild type/LOH indeterminate was required to be clinically relevant and at least as large as what would be needed to 
achieve ‘‘statistical significance’’ in an analysis conducted in the entire intent-to-treat population.  
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Table S1: Inclusion and exclusion criteria 
All patients enrolled into the study must have met all of the following inclusion criteria:  
1. Signed an Institutional Review Board/Independent Ethics Committee-approved informed consent form prior to any study-specific 
evaluation  
2. Were ≥18 years of age at the time the informed consent form was signed  
3. Had a histologically confirmed diagnosis of high-grade (Grade 2 or 3) serous or endometrioid epithelial ovarian, fallopian tube, or primary 
peritoneal cancer  
- For mixed histology, >50% of the primary tumour must have been confirmed to be high-grade serous or endometrioid  
- Grade 2 tumours classified under a 3-tier system should have been re-reviewed by local pathology and confirmed as high-grade 
under the 2-tier system  
4. Received prior platinum-based therapy and have platinum-sensitive disease (i.e. documented radiologic disease progression >6 months 
following the last dose of the penultimate platinum administered)  
- Received ≥2 prior platinum-based treatment regimens, including platinum-based regimen that must have been administered 
immediately prior to maintenance therapy in this trial. In addition, up to 1 non-platinum chemotherapy regimen was permitted. 
Prior hormonal therapy was permitted; this treatment were not be counted as a non-platinum regimen.  
- There was no upper limit on the number of prior platinum-based regimens that may have been received, but the patient must have 
been sensitive to the penultimate platinum-based regimen administered.  
- If both neoadjuvant and adjuvant treatment were administered pre/post any debulking surgery, this was considered 1 treatment 
regimen  
- Prior maintenance therapy following a prior treatment regimen was permitted, with the exception of the regimen received 
immediately prior to maintenance in this study. No anticancer therapy was permitted to be administered as maintenance treatment 
in the interval period between completion of the most recent platinum-based therapy and initiation of study drug in this trial.  
5. Achieved best response of either CR or PR to the most recent platinum-based regimen administered and was randomised to study treatment 
within 8 weeks of the last dose of platinum received  
- The most recent platinum-based regimen must have been a chemotherapy doublet. The choice of the platinum and the 2nd 
chemotherapy agent was per Investigator’ discretion. (This criterion was added through an amendment to the protocol on 
November 4, 2014, 7 months after enrolment had started) 
- A minimum of 4 cycles of platinum chemotherapy must have been administered. There was no cap on the maximum number of 
cycles; however, additional cycles of treatment administered following completion of therapy for the specific purpose of enabling 
patient eligibility and randomisation within 8 weeks of the last platinum dose was not permitted.  
- A CR was defined as a complete radiologic response per RECIST v1.1, i.e. absence of any detectable disease and CA-125 <ULN  
- A PR was defined as either a partial response per RECIST v1.1 (if disease was measurable prior to chemotherapy) or a serologic 
response per GCIG CA-125 response criteria (if disease was not measurable according to RECIST v1.1)  
- CA-125 must also have been <ULN for all responses classified as a PR  
- R0 surgery (no visible tumour) or R1 surgery (residual disease <1 cm) as a component of the most recent treatment regimen was 
not permitted. The response assessment must have been determined solely in relation to the chemotherapy regimen administered. 
The presence of measurable disease or CA-125 >2 x ULN immediately prior to the chemotherapy regimen was required.  
- Responses must have been maintained through the completion of chemotherapy and during the interval period between completion 
of chemotherapy and entry in the study  
- All disease assessments performed prior to and during this chemotherapy regimen must have been adequately documented in the 
patient’s medical record  
6. Had sufficient archival formalin-fixed paraffin-embedded (FFPE) tumour tissue (1 x 4 µm section for haematoxylin and eosin [H&E] stain 
and approximately 8 – 12 x 10 µm sections, or equivalent) available for planned analyses.  
- The most recently collected tumour tissue sample should have been provided, if available  
- Submission of a tumour block was preferred; if sections were provided, these must all have been from the same tumour sample  
- Sample must have been received at the central laboratory at least 3 weeks prior to planned start of treatment in order to enable 
stratification for randomisation  
7. Had CA-125 measurement that was < ULN  
8. Had ECOG performance status of 0 to 1  
9. Had adequate organ function confirmed by the following laboratory values obtained within 14 days of the first dose of study drug:  
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- Bone Marrow Function: absolute neutrophil count (ANC) ≥1.5 × 109/L; platelets >100 × 109/L; haemoglobin ≥9 g/dL  
- Hepatic Function: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3 × ULN (if liver metastases, then ≤5 × 
ULN); bilirubin ≤1.5 × ULN (<2 x ULN if hyperbilirubinemia was due to Gilbert’s syndrome)  
- Renal Function: Serum creatinine ≤1.5 × ULN or estimated glomerular filtration rate (GFR) ≥45 mL/min using the Cockcroft 
Gault formula  
Patients were excluded from participation if any of the following criteria applied:  
1. History of a prior malignancy except:  
- Curatively treated non-melanoma skin cancer  
- Breast cancer treated curatively >3 years ago, or other solid tumour treated curatively >5 years ago, without evidence of recurrence  
- Synchronous endometrioid endometrial cancer (Stage 1A G1/G2)  
2. Prior treatment with any PARP inhibitor, including oral or intravenous rucaparib; patients who previously received iniparib were eligible.  
3. Required drainage of ascites during the final 2 cycles of their last platinum-based regimen and/or during the period between the last dose of 
chemotherapy of that regimen and randomisation to maintenance treatment in this study  
4. Symptomatic and/or untreated central nervous system (CNS) metastases. Patients with asymptomatic previously treated CNS metastases 
were eligible provided they have been clinically stable for at least 4 weeks.  
5. Pre-existing duodenal stent and/or any gastrointestinal disorder or defect that would have, in the opinion of the Investigator, interfered with 
absorption of study drug  
6. Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness, or history of chronic 
hepatitis B or C  
7. Pregnant or breast feeding. Women of childbearing potential must have had a negative serum pregnancy test <3 days prior to first dose of 
study drug  
8. Received treatment with chemotherapy, radiation, antibody therapy or other immunotherapy, gene therapy, vaccine therapy, angiogenesis 
inhibitors, or experimental drugs ≤14 days prior to first dose of study drug and/or ongoing adverse effects from such treatment > NCI CTCAE 
Grade 1, with the exception of Grade 2 non-hematologic toxicity such as alopecia, peripheral neuropathy, and related effects of prior 
chemotherapy that were unlikely to be exacerbated by treatment with study drug  
- Ongoing hormonal treatment for previously treated breast cancer was permitted  
9. Received administration of strong CYP1A2 or CYP3A4 inhibitors ≤7 days prior to first dose of study drug or had on-going requirements 
for these medications (Appendix F)  
10. Non-study related minor surgical procedure ≤5 days, or major surgical procedure ≤21 days, prior to first dose of study drug; in all cases, 
the patient must have been sufficiently recovered and stable before treatment administration  
11. Presence of any other condition that may have increased the risk associated with study participation or may have interfered with the 
interpretation of study results, and, in the opinion of the investigator, would have made the patient inappropriate for entry into the study  
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Table S2: Panel of 30 genes associated with homologous recombination utilised for stratification  
BRCA Other Homologous Recombination Genes  
BRCA1 
BRCA2 
ATM 
ATR 
ATRX 
BARD1 
BLM 
BRIP1 
CHEK1 
CHEK2 
FANCA 
FANCC 
FANCD2 
FANCE 
FANCF 
FANCG 
FANCI 
FANCL 
FANCM 
MRE11A 
NBN 
PALB2 
RAD50 
RAD51 
RAD51B 
RAD51C 
RAD51D 
RAD52 
RAD54L 
RPA1 
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Table S3: Objective response rates in patients with measurable disease at baseline 
 
BRCA Mutant  HRD   Intent-to-Treat Population 
Rucaparib 
(n=40) 
Placebo 
(n=23) 
Rucaparib 
(n=85) 
Placebo 
(n=41) 
Rucaparib 
(n=141) 
Placebo 
(n=66) 
Investigator-assessed RECIST 
ORR (confirmed CR+PR) 
15 (37.5%) 
[22.7%-54.2%] 
2 (8.7%) 
[1.1%-28.0%] 
23 (27.1%) 
[18.0%-37.8%] 
3 (7.3%) 
[1.5%-19.9%] 
26 (18.4%) 
[12.4%-25.8%] 
5 (7.6%) 
[2.5%-16.8%] 
Complete response 7 (17.5%) 0 (0%) 10 (11.8%) 0 (0%) 10 (7.1%) 1 (1.5%) 
Partial response 8 (20.0%) 2 (8.7%) 13 (15.3%) 3 (7.3%) 16 (11.3%) 4 (6.1%) 
Stable disease 19 (47.5%) 8 (34.8%) 43 (50.6%) 17 (41.5%) 71 (50.4%) 29 (43.9%) 
Progressive disease 5 (12.5%) 13 (56.5%) 18 (21.2%) 21 (51.2%) 38 (27.0%) 32 (48.5%) 
Not evaluable 1 (2.5%) 0 (0%) 1 (1.2%) 0 (0%) 6 (4.3%) 0 (0%) 
Data are n (%) [95% CI]. CI=confidence interval; HRD=homologous recombination deficient; ORR=objective response rate; RECIST=Response 
Evaluation Criteria In Solid Tumors version 1.1.  
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Table S4: Treatment-emergent adverse events leading to dose reduction and/or treatment interruption in 
≥1% of patients 
 Dose Reduction Treatment Interruption Dose Reduction and/or 
Treatment Interruption 
Adverse event Rucaparib 
(n=372) 
Placebo 
(n=189) 
Rucaparib 
(n=372) 
Placebo 
(n=189) 
Rucaparib 
(n=372) 
Placebo 
(n=189) 
Any adverse event leading to dose 
reduction or interruption 203 (54.6%) 8 (4.2%) 237 (63.7%) 19 (10.1%) 263 (70.7%) 20 (10.6%) 
Thrombocytopenia; platelet count 
decreased 39 (10.5%) 0 64 (17.2%) 0 67 (18.0%) 0 
Anaemia; decreased haemoglobin 45 (12.1%) 0 51 (13.7%) 1 (0.5%) 62 (16.7%) 1 (0.5%) 
Nausea 37 (9.9%) 1 (0.5%) 38 (10.2%) 2 (1.1%) 56 (15.1%) 2 (1.1%) 
Increase in alanine aminotransferase or 
aspartate aminotransferase 41 (11.0%) 0 39 (10.5%) 0 50 (13.4%) 0 
Asthenia; fatigue 33 (8.9%) 4 (2.1%) 32 (8.6%) 6 (3.2%) 46 (12.4%) 6 (3.2%) 
Vomiting 12 (3.2%) 0 32 (8.6%) 2 (1.1%) 35 (9.4%) 2 (1.1%) 
Neutropenia; neutrophil count 
decreased 13 (3.5%) 0 23 (6.2%) 1 (0.5%) 26 (7.0%) 1 (0.5%) 
Increase in blood creatinine 14 (3.8%) 0 12 (3.2%) 0 17 (4.6%) 0 
Diarrhoea 5 (1.3%) 0 11 (3.0%) 0 14 (3.8%) 0 
Abdominal pain 2 (0.5%) 0 12 (3.2%) 0 12 (3.2%) 0 
Constipation 5 (1.3%) 0 6 (1.6%) 1 (0.5%) 10 (2.7%) 1 (0.5%) 
Abdominal pain upper 3 (0.8%) 0 5 (1.3%) 0 6 (1.6%) 0 
Increase in transaminases 5 (1.3%) 0 4 (1.1%) 0 6 (1.6%) 0 
Rash 2 (0.5%) 0 5 (1.3%) 0 6 (1.6%) 0 
Dysgeusia 5 (1.3%) 0 3 (0.8%) 0 5 (1.3%) 0 
Dyspepsia 4 (1.1%) 0 3 (0.8%) 1 (0.5%) 5 (1.3%) 1 (0.5%) 
Urinary tract infection 0 1 (0.5%) 5 (1.3%) 0 5 (1.3%) 1 (0.5%) 
Mucosal inflammation 1 (0.3%) 2 (1.1%) 4 (1.1%) 1 (0.5%) 4 (1.1%) 2 (1.1%) 
Photosensitivity reaction 3 (0.8%) 0 3 (0.8%) 0 4 (1.1%) 0 
Pyrexia 0 0 4 (1.1%) 0 4 (1.1%) 0 
Small intestine obstruction 0 0 4 (1.1%) 1 (0.5%) 4 (1.1%) 1 (0.5%) 
White blood count decreased 0 0 4 (1.1%) 0 4 (1.1%) 0 
Decreased appetite 1 (0.3%) 1 (0.5%) 3 (0.8%) 2 (1.1%) 3 (0.8%) 2 (1.1%) 
Dizziness 1 (0.3%) 0 1 (0.3%) 2 (1.1%) 2 (0.5%) 2 (1.1%) 
Lung infection 0 1 (0.5%) 0 2 (1.1%) 0 2 (1.1%) 
Data are n (%) in the safety population, all patients who received at least one dose of protocol-specified treatment; a patient may have had a 
dose reduction or interruption as a result of more than one adverse event. Data are sorted based on incidence of reduction and/or interruption 
in the rucaparib arm. 
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Table S5: Treatment-emergent adverse events leading to dose discontinuation 
Adverse event Rucaparib 
(n=372) 
Placebo 
(n=189) 
Any adverse event leading to discontinuation 50 (13.4%) 3 (1.6%) 
Anaemia; decreased haemoglobin 11 (3.0%) 0 
Thrombocytopenia; platelet count decreased 10 (2.7%) 0 
Nausea 9 (2.4%) 1 (0.5%) 
Asthenia; fatigue 6 (1.6%) 0 
Vomiting 5 (1.3%) 1 (0.5%) 
Febrile neutropenia 3 (0.8%) 0 
Acute kidney injury 2 (0.5%) 0 
Increase in alanine aminotransferase or 
aspartate aminotransferase 2 (0.5%) 0 
Myelodysplastic syndrome 2 (0.5%) 0 
Neutropenia; neutrophil count decreased 2 (0.5%) 0 
Weight decreased 2 (0.5%) 0 
Abdominal pain 1 (0.3%) 0 
Acute myeloid leukaemia 1 (0.3%) 0 
Acute respiratory distress syndrome 1 (0.3%) 0 
Amnesia 1 (0.3%) 0 
Cardiac arrest 1 (0.3%) 0 
Confusional state 1 (0.3%) 0 
Dyspepsia 1 (0.3%) 0 
Dyspnoea 1 (0.3%) 0 
Histiocytosis haematophagic 1 (0.3%) 0 
Lethargy 1 (0.3%) 0 
Leukopenia 1 (0.3%) 0 
Mental status change 1 (0.3%) 0 
Neutropenic colitis 1 (0.3%) 0 
Pancytopenia 1 (0.3%) 0 
Photosensitivity reaction 1 (0.3%) 0 
Renal impairment 1 (0.3%) 0 
Seizure 1 (0.3%) 0 
Sepsis 1 (0.3%) 0 
Swelling face 1 (0.3%) 0 
Tachycardia 1 (0.3%) 0 
Decreased appetite 0 1 (0.5%) 
Intestinal obstruction 0 1 (0.5%) 
Small intestinal obstruction 0 1 (0.5%) 
Data are n (%) in the safety population, all patients who received at least one dose 
of protocol-specified treatment; a patient may have discontinued as a result of 
more than one adverse event.  
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Figure S1. Diagram of efficacy analysis cohorts 
 
HRD=homologous recombination deficient; Indet.=indeterminate; ITT=intent-to-treat; LOH=loss of heterozygosity.
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Figure S2. Investigator-assessed progression-free survival by other mutation categorisations 
 
CI=confidence interval; HR=hazard ratio HRR=homologous recombination repair; ITT=intent-to-treat; LOH=loss 
of heterozygosity.  
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Figure S3. Blinded, independent central radiology review-assessed progression-free survival in patients with a 
BRCA wild-type carcinoma  
Kaplan-Meier estimates of progression-free survival as assessed by BICR in the rucaparib (blue) and placebo (red) 
arms for patients with a BRCA wild-type carcinoma with (A) LOH high and (B) LOH low. 
 
BICR=blinded, independent central radiology review; CI=confidence interval; HR=hazard ratio; LOH=loss of 
heterozygosity. 
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Figure S4. Mean baseline and on-treatment values for haematologic laboratory parameters 
(A) Haemoglobin, (B) neutrophil, and (C) platelet values for patients in the safety population with baseline and 
postbaseline results. Horizontal lines in graphs represent the upper and lower limits of normal for each laboratory 
parameter. Error bars represent standard error of the mean.  
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Figure S5. Mean baseline and on-treatment values for chemistry laboratory parameters 
(A) Alanine aminotransferase, (B) aspartate aminotransferase, (C) bilirubin, and (D) creatinine values for patients in 
the safety population with baseline and postbaseline results. Horizontal lines in graphs represent the upper and lower 
limits of normal for each laboratory parameter. Error bars represent standard error of the mean. 
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